Nuvalent, Inc.

Join us at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, where we’ll present clinical updates from our #ALK+ #NSCLC and ROS1+ programs, including: 📊 Pivotal data in TKI pre-treated patients with advanced ALK+ NSCLC treated in the ALKOVE-1 Phase 1/2 clinical trial, in addition to preliminary data for TKI-naïve patients 🔬 First presentation of preliminary data in patients with advanced ROS1+ solid tumors other than NSCLC treated in the ARROS-1 Phase 1/2 clinical trial Learn more here. https://lnkd.in/gSknsYkC #ASCO26

New faces, same great mission! Please join us in welcoming Simone, Laura, Amanda, Allison, Katie, Cynthia, and Geoffrey to the NuCrew! We’re thrilled to have you here!

We recognize the emotional weight of a #LungCancer journey—the uncertainty, and the resilience and strength it takes to keep moving forward. You are not alone. This #MentalHealthAwareness month, find strength through support. Connect with patient advocacy organizations like ALK Positive Inc. and The ROS1ders, where patients and caregivers come together to share, listen, and uplift one another. LUNGevity Foundation GO2 for Lung Cancer Lung Cancer Foundation of America Lung Cancer Research Foundation

This morning, we reported our Q1 2026 financial results, along with recent pipeline and business progress and anticipated milestones. ✔️ NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC 🎯 NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review with PDUFA target action date of 9/18/26 📊 Submission for potential label expansion of zidesamtinib in TKI-naïve advanced ROS1-positive NSCLC planned for the second half of 2026 👥 Strengthened leadership team with key internal promotions 📅 Participation in TD Cowen 7th Annual Oncology Innovation Summit virtually and Jefferies 2026 Healthcare Conference in New York Learn more here. https://lnkd.in/e2G_gCwa

The #NuCrew had a great time at the 2026 American Association for Cancer Research Annual Meeting engaging with the #oncology community and presenting new data for our ROS1+ #NSCLC program. Thank you to everyone who stopped by our posters to share insights and ask questions! #AACR26

We’re growing our team with purpose, always keeping patients at the center of what we do. Explore our latest roles in Clinical Operations, Biostatistics & Programming, Supply Chain, and more for opportunities to join the #NuCrew. https://lnkd.in/gtCMkVzG

Join us in welcoming Riley, Ashley, Kyle, and Tiffany to the #NuCrew! 🎉 We’re excited to have them on board!

Join us at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago where we'll present clinical updates from our #ALK+ #NSCLC and ROS1+ programs, including: 📊 Pivotal data for TKI pre-treated patients with advanced ALK+ NSCLC treated in the ALKOVE-1 Phase 1/2 clinical trial, in addition to preliminary data for TKI-naïve patients. 🔬Preliminary data in patients with advanced ROS1+ solid tumors outside of NSCLC treated in the ARROS-1 Phase 1/2 clinical trial. Learn more: https://lnkd.in/ghSES9BK #ASCO26

This week at the American Association for Cancer Research's 2026 Annual Meeting, we’re pleased to share new clinical and preclinical data for our ROS1+ #NSCLC program, including: 📊 Clinical data from a subset of TKI pre-treated ROS1+ NSCLC patients from the ARROS-1 trial previously treated with the most recently approved ROS1 inhibitors, including those with CNS disease or ROS1 resistance mutations. 🔬Preclinical data on brain penetrance and intracranial activity among ROS1 inhibitors. Learn more here. https://lnkd.in/ggQZYcNv #AACR26

During #CancerPrevention and #EarlyDetection Month, we’re honoring the stories of patients like Luna and Brandi, each navigating #LungCancer with strength, resilience and the support of their communities. Through biomarker testing, they discovered ROS1 and ALK mutations that helped guide their treatment journeys. Their stories are a reminder that: 🫁 Lung cancer can affect anyone 🧪Testing matters 👥 No one should face this alone 💙 Knowledge can lead to hope Learn about ROS1 and ALK+ NSCLC and more → elevatelungcancercare.com. #ALKPositive #ROS1Positive